Conclusions

Armitage JO and Cheson BD: Interpretation of clinical trials in diffuse large cell lymphomas. J Clin Oncol 1988 (6):1335–1347PubMedGoogle Scholar

NCI Hodgkin’s Classification Project Writing Committee: Classification of non-Hodgkin’s lymphomas: reproducibility of major classification systems. Cancer 1985 (55):91–95CrossRefGoogle Scholar

Longo DL and De Vita VT: Malignant lymphomas. In: HM Pinedo and BA Chabner (eds) Cancer Chemotherapy Annual 8. Elsevier Science Publishers, Amsterdam 1986 pp 261–304Google Scholar

Coiffier B, Brousse N, Peuchmaur M, Berger F, Gisselbrecht C, Bryon PA, Diebold J: Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. Ann Oncol 1989 (1) in pressGoogle Scholar

Klimo P and Connors JM: MACOP-B chemotherapy for the treatment of diffuse large-cell lymphomas. Ann Intern Med 1985 (102):596–602PubMedGoogle Scholar

Miller TP, Dahlberg S, Jones SE et al: ProMACE-CytaBOM is active with acceptable toxicity in patients with unfavourable non-Hodgkin lymphomas: a group-wide SWOG study. Proc Am Soc Clin Oncol 1987(6):197Google Scholar

Longo D, De Vita V, Duffey PL et al: Randomized trial of ProMACE-MOPP vs Pro-MACE-CytaBOM in stage II-IV aggressive non-Hodgkin’s lymphoma. Proc Am Soc Clin Oncol 1987 (6):206Google Scholar

Canellos GP, Skarin AT, Klatt MM et al: m-BACOP combination chemotherapy regimen in the treatment of diffuse large cell lymphoma. Semin Hematol 1981 (24):2–7Google Scholar

Coiffier B, Gisselbrecht C, Herbrecht R, Tilly H, Bosly A, Brousse N: LNH-84 regimen: a multicenter study on intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 1989 (7):1018–1026PubMedGoogle Scholar

Coiffier B, Lepage E: Prognosis of aggressive lymphomas: a study of five prognostic models with patients included in the LNH-84 regimen. Blood 1989Google Scholar

Camitta BM, Lauer SJ, Casper JT, Kirchner PA, Kum LE, Oechler HW, Adair SE: Effectiveness of a six-drug regimen (APO) without local irradiation for treatment of mediastinal lymphoblastic lymphoma in children. Cancer 1985 (56):738–741PubMedCrossRefGoogle Scholar

Amendola BE, Hutchinson R, Amendola MA, Schnitzer B: Childhood non-Hodgkin’s lymphoma: a review of treatment results in 53 children. Eur Paediatr Haematol Oncol 1984 (1):213CrossRefGoogle Scholar

Boguslawska-Jaworska J, Koscielnak E, Sroczynska M, Sonta-Jakimczyk, Armata J, Balwierz W, Ciepeilewska D, Kaczmarek-Kanold M, Ochocka M, Radwanska U, Rokicka-Milewska R: Evaluation of the LSA₂-L2 protocol for treatment of childhood non-Hodgkin’s lymphoma. A report from the Polish Children’s Leukemia/Lymphoma Study Group. Am J Pediatr Hematol Oncol 1984 (6):363–370PubMedCrossRefGoogle Scholar

Sullivan MP, Ramirez I: Curability of Burkitt’s lymphoma with high-dose cyclophosphamide-high-dose methotrexate therapy and intrathecal chemoprophilaxis. J Clin Oncol 1985 (3):627–636PubMedGoogle Scholar

Tirelli U, Zagonel V, Serraino D, Thomas J, Hoerni B, Tangury A, Ruhl U, Bey P, Tubiana N, Breed WPM, Roozendaal KJ, Hagenbeek A, Hupperets PS and Somers R: Non-Hodgkin’s lymphomas in 137 patients aged 70 years or older: a retrospective European organization for research and treatment of cancer lymphoma group study. J Clin Oncol 1988 (6):1708–1713PubMedGoogle Scholar

Meyers PA, Potter VP, Wollner N, Exelby P: Bowel perforation during initial treatment for childhood non-Hodgkin’s lymphoma. Cancer 1985 (56):259–261PubMedCrossRefGoogle Scholar

Surbone A, Longo DL, De Vita VT, Ihde DC, Duffey PL, Jaffe ES, Solomon D, Hubbard SM and Young RC: Residual abdominal masses in aggressive non-Hodgkin’s lymphoma after combination chemotherapy: significance and management. J Clin Oncol 1988 (6):1832–1837PubMedGoogle Scholar

Gisselbrecht C, Oksenhendler E, Farcet JP, Dombret H, Coiffier B, Thyss A, Raphael M: Treatment approaches for non-Hodgkin’s lymphomas (NHL) associated with human immunodeficiency virus (HIV). Proc Am Soc Clin Oncol 1989 (8):3Google Scholar